MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine To guage many intravenous doses of sifalimumab, in adult people with dermatomyositis or polymyositis (NCT00533091). Principal trial targets have been To guage the protection and tolerability of sifalimumab in dermatomyositis or polymyositis clients, while one of many exploratory https://douglasx111mxi5.wikipowell.com/user